Fig. 5: Minimal MOG protein reduction was observed across CNS regions following neonatal ICV injection of AAV-CRISPR/sgMOG. | Gene Therapy

Fig. 5: Minimal MOG protein reduction was observed across CNS regions following neonatal ICV injection of AAV-CRISPR/sgMOG.

From: Use of CRISPR/Cas9-mediated disruption of CNS cell type genes to profile transduction of AAV by neonatal intracerebroventricular delivery in mice

Fig. 5

Viruses (ssAAV-U6-sgMOG-CBA-NLS-eGFP) were injected at either a low (a 5E10 vg) or high dose (b 20E10 vg) in neonatal mice. After 6 weeks, multiple brain regions and spinal cord were dissected and the amount of the MOG proteins remaining undisrupted in the bulk tissues was quantified using the Protein Simple Peggy Sue. For quantification of each AAV variant within each CNS region: the averages of the MOG signals from AAV-CRISPR/sgLacZ (not shown) were normalized to 100% as baseline (dotted line), relative MOG protein levels are presented as mean ± s.e.m., two-way ANOVA followed by Tukey’s test, from baseline (sgLacZ) #p < 0.05.

Back to article page